文献速递妇科

与卵巢癌肿瘤检测并行的主流化检测以提高基因检测接受率

Mainstreaming in parallel with ovarian cancer tumor testing to improve genetic testing uptake.
PubMed 文献 · Gynecol Oncol · 2024-03-15

在单一机构中,对2015年7月1日至2022年3月31日新诊断的上皮性卵巢癌患者进行回顾性分析,2019年1月起在肿瘤门诊实施与肿瘤检测(MSK-IMPACT)并行的主流化基因检测。1742例患者中1591例(91%)接受了基因检测,主流化后检测率从87%升至95%(p < 0.001)。调整组织学、分期和婚姻状态后,主流化与基因检测可能性增加独立相关(OR 3.77;95% CI: 2.56-5.66)。

要点

  • 主流化实施后基因检测率从87%升至95%(p < 0.001)。
  • 未检测主要原因:无医生推荐(76/151,50%)和流程问题(38/151,25%)。
  • 高级别浆液性组织学、晚期(III/IV期)及有配偶/伴侣者检测率更高。

核心结论

  • 主流化提高了上皮性卵巢癌患者基因检测的可能性。
  • 无配偶/伴侣、非高级别浆液性组织学和早期疾病患者检测率较低,是未来干预的潜在领域。

研究设计与样本

  • 回顾性分析,纳入2015年7月1日至2022年3月31日在本机构新诊断的上皮性卵巢癌患者,共1742例。
  • 2019年1月起在肿瘤门诊实施与肿瘤检测(MSK-IMPACT)并行的主流化基因检测。
  • 采用逻辑回归模型识别与基因检测相关的变量。

主要发现

  • 1742例患者中1591例(91%)接受了基因检测。
  • 主流化后基因检测率从87%升至95%(p < 0.001)。
  • 151例未检测患者中,无医生推荐76例(50%),流程问题38例(25%),拒绝14例(9%),医学并发症阻止检测7例(4.6%)。
  • 高级别浆液性组织学、晚期(III/IV期)及有配偶/伴侣与基因检测接受率增加相关(p < 0.01)。
  • 社会健康决定因素变量中,保险、Yost评分、语言、合并症、就业或种族/族裔无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Although genetic testing (GT) is universally recommended for patients with epithelial ovarian cancer (EOC), rates are low (34%). In 1/2019, we implemented mainstreaming-GT in parallel with tumor testing via MSK-IMPACT within oncology clinics. We sought to determine GT rates pre/post-mainstreaming and patient characteristics associated with GT. METHODS: Patients with newly diagnosed EOC seen at our institution from 7/1/2015-3/31/2022 were included. Clinical data were abstracted including social determinants of health (SDOH) variables, race/ethnicity, marital status, insurance, language, comorbidities, employment, and Yost index, a measure of socioeconomic status. GT rates were calculated overall and pre-/post-mainstreaming (1/2019). Logistic regression models were fit to identify variables associated with GT. RESULTS: Of 1742 patients with EOC, 1591 (91%) underwent GT. Rates of GT increased from 87% to 95% after mainstreaming (p < 0.001). Among 151 patients not undergoing GT, major reasons were lack of provider recommendation (n = 76, 50%) and logistical issues (n = 38, 25%) with few declining (n = 14, 9%) or having medical complications preventing GT (n = 7, 4.6%). High-grade serous histology, advanced stage (III/IV), and having a spouse/partner were associated with increased GT uptake (p < 0.01). Among SDOH variables, there were no differences by insurance, Yost score, language, comorbidities, employment, or race/ethnicity. In multivariable models, likelihood of GT increased with mainstreaming, even after adjustment for histology, stage, and marital status (OR 3.77; 95% CI: 2.56-5.66). CONCLUSIONS: Mainstreaming increased the likelihood of GT in patients with EOC. We found lower testing rates in patients without partners/spouses, non-high-grade serous histology, and early-stage disease, representing potential areas for future interventions.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Byrne M, Sia TY, Fong C, et al. Mainstreaming in parallel with ovarian cancer tumor testing to improve genetic testing uptake. Gynecol Oncol. 2024. PMID: 38493020. doi:10.1016/j.ygyno.2024.03.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。